Menarini and Ryvu Announce First JASPIS-01 Clinical Data

The companies announced first clinical data from the Phase II study of dapolsertib in heavily pretreated relapsed or refractory aggressive B-cell non-Hodgkin lymphoma at the 2026 ASH Annual Meeting.